Thursday, 15 October 2026European Markets

OREGE Stock Was Up By 9.09% On Wednesday

Loading stream...

(vianews) - the market ended the session with orege (orege.pa) rising 9.09% to €0.44 on wednesday while cac 40 fell 0.16% to €7,531.22.

orege's last close was €0.41, 46.31% below its 52-week high of €0.76.

about orege

orege société anonyme designs, develops, operates, manufactures, and markets municipal and industrial sludge, and effluents treatment solutions in france, the united states, japan, germany, and the united kingdom. the company offers slg solution for conditioning, treating, and recovering municipal and industrial sludge; slg-f, a combination of slg conditioning solution; and flosep for sludge separation and thickening tool. it also provides after-sales, installation and commissioning, operator training, warranty extensions, maintenance, and process optimization packages. the company was incorporated in 2005 and is headquartered in voisins-le-bretonneux, france. orege société anonyme is a subsidiary of eren groupe sa.

earnings per share

as for profitability, orege has a trailing twelve months eps of €-0.15.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, orege's stock is considered to be overbought (>=80).

moving average

orege's value is under its 50-day moving average of €0.44 and above its 200-day moving average of €0.42.

more news about orege (orege.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com